NCT00632723View on ClinicalTrials.gov

IRESSA™ (Gefitinib) in Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

April 30, 2001

Study Completion Date

October 31, 2005

Conditions

Breast Cancer

Interventions

DRUG

gefitinib (IRESSA™, ZD1839)

250 mg tablet; daily dose 500 mg daily

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY